BULLOUS PEMPHIGOID ASSOCIATED WITH SITAGLIPTIN USE

A CASE REPORT

Authors

  • Ma. Guia Estrella Dela Cruz Chinese General Hospital and Medical Center, Manila, Philippines
  • Mark Henry Joven University of Santo Tomas Faculty of Medicine and Surgery, Manila, Philippines
  • Clarisse Mendoza Research Institute for Tropical Medicine, Muntinlupa, Philippines
  • Emmerson Gale Vista Research Institute for Tropical Medicine, Muntinlupa, Philippines

Keywords:

sitagliptin, dpp-iv inhibitors, bullous pemphigoid

Abstract

INTRODUCTION
DPP-IV inhibitors are considered one of the safest anti-diabetes drugs given its low hypoglycemic risk and neutral effects on weight. Recently, cases of bullous pemphigoid have been reported on patients with type 2 diabetes treated with DPP-IV inhibitors.

CASE
A 70-year-old Filipino male of Chinese descent presented with pruritic eczematous papular rash on both shins. Lesions progressed to blisters in the trunk and extremities. Medical history was significant for T2DM and hypertension. He was on sitagliptin 50 mg daily (started a month prior) and losartan 50 mg daily.

CONCLUSION
We present a patient with T2DM on sitagliptin who presented with bullous pemphigoid. Physicians should be aware of this association since early detection may circumvent its progression and avert complications.

Downloads

Download data is not yet available.

References

*

Downloads

Published

2022-06-08

How to Cite

Dela Cruz, M. G. E., Joven, M. H., Mendoza, C., & Vista, E. G. (2022). BULLOUS PEMPHIGOID ASSOCIATED WITH SITAGLIPTIN USE: A CASE REPORT. Journal of the ASEAN Federation of Endocrine Societies, 34(2), 56. Retrieved from https://www.asean-endocrinejournal.org/index.php/JAFES/article/view/2049

Issue

Vol. 34 No. 2 (2019): AFES Book of Abstracts (Supplement)

Section

Abstracts of Case Reports | Prediabetes, Diabetes, Hypoglycemia

License

The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.

To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.

A written agreement will be issued to the requester once permission has been granted.